Abcam, ab243974, Human GLP1 (7-36) Antibody Pair - BSA and Azide free

Size: 10 x 96Tests
Human GLP1 (7-36) Antibody Pair - BSA and Azide free is a kit containing recombinant capture and detector antibodies in a carrier-free formulation for the measurement of Human GLP1 (7-36).
Key facts
Reacts with:Human,
Assay type:ELISA set,
Range:59.6 - 1000 pg/mL,
Assay Platform:Reagents

Product details:
The Antibody Pair can be used to quantify Human GLP1. BSA and Azide free antibody pairs include unconjugated capture and detector antibodies suitable for sandwich ELISAs. The antibodies are provided at an approximate concentration of 1 mg/ml as measured by the protein A280 method. The recommended antibody orientation is based on internal optimization for ELISA-based assays. Antibody orientation is assay dependent and needs to be optimized for each assay type. Both capture and detector antibodies are rabbit monoclonal antibodies delivering consistent, specific, and sensitive results.
For additional information on the performance of the antibody pair, see the equivalent SimpleStep ELISA® Kit (
ab184857
), which uses the same antibodies. However, due to differences in their formulation, this antibody pair cannot be used with the consumables provided with our SimpleStep ELISA Kits. Please note that the range provided for the pairs is only an estimation based on the performance of the related product using the same antibody pair. Performance of the antibody pair will depend on the specific characteristics of your assay. We guarantee the product works in sandwich ELISA, but we do not guarantee the sensitivity or dynamic range of the antibody pair in your assay.
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with <1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
The pair can be used in variety of assays and platforms including but not limited to:
Sandwich ELISA
FRET/TR-FRET/HTRF
Meso Scale Discovery
Bead-based assays
AlphaLISA
/AlphaScreen
DELFIA
immunoassays
and Single Molecule Counting (SMC™) immunoassays
Multiplex
Our antibody pairs are supplied in a carrier-free format that is conjugation-ready:
Buffer free of BSA, sodium azide, and glycerol for higher conjugation efficiency.
Concentration of ~1 mg/ml as measured by the protein A280 method.
We can label antibodies for you: get in touch today to discuss how we can help accelerate your assay development with custom conjugation services.
Pairs are screened in biological samples, including plasma and serum, to ensure specificity in complex samples.
Please note:
The recommended antibody orientation is based on internal optimization in sandwich ELISA. Antibody orientation is assay dependent and needs to be optimized for each assay type.
The range provided for this antibody pair is based on initial sandwich ELISA validation data using recombinant protein. Performance and range of the antibody pair will depend on the specific characteristics of your assay, including standard protein selection.
We guarantee the product works in sandwich ELISA, but we do not guarantee the sensitivity or dynamic range of the antibodies in other assays.
Antibody properties:
Capture antibody:
recombinant rabbit monoclonal (unconjugated) – 100 µg
Detector antibody:
recombinant rabbit monoclonal (unconjugated) - 100 µg
Concentration
: ~1 mg/ml
Storage buffer:
100% PBS
Liquid
Isotype:
Recombinant monoclonal antibodies offer several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free production
Meso Scale Discovery and MSD are registered trademarks of Meso Scale Diagnostics, LLC.
AlphaLISA, AlphaScreen, and DELFIA are registered trademarks of PerkinElmer, Inc.
Simoa is a registered trademark of Quanterix, Inc.
SMC is a registered trademark of Merck KGaA, Darmstadt, Germany.

Properties and Storage Information:
Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-+4°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
GLP-1 (7-36) also known as glucagon-like peptide-1 is a peptide hormone that is integral to glucose metabolism. It has a molecular mass of approximately 3.8 kDa and is mainly expressed in the intestinal L-cells. It also exists in neurons within the brainstem. GLP-1 (7-36) plays a role in stimulating insulin secretion from the pancreas in response to ingested nutrients. It interacts directly with the GLP-1 receptor a G protein-coupled receptor to exert its effects.
Biological function summary
The peptide regulates blood glucose levels by promoting insulin release and inhibiting glucagon secretion. GLP-1 (7-36) also slows gastric emptying and reduces appetite which contributes to its role in energy balance. It does not function as part of a larger protein complex but its active form can be derived from the proglucagon protein precursor. The peptide has additional neuroprotective effects and supports beta-cell proliferation and survival further highlighting its multifaceted roles in metabolism.
Pathways
This peptide acts significantly within the incretin pathway a critical regulator of glucose homeostasis. The GLP-1 receptor is activated upon binding with GLP-1 (7-36) leading to the stimulation of downstream signaling processes involving proteins like PKA and PI3K which promote insulin secretion. Additionally its interaction with DPP-4 enzyme is notable as DPP-4 degrades GLP-1 (7-36) diminishing its activity and influencing glucose regulation pathways.
Altered levels of GLP-1 (7-36) relate to conditions like type 2 diabetes and obesity. Its ability to enhance insulin secretion helps manage hyperglycemia in diabetic patients. The peptide also associates indirectly with liraglutide a GLP-1 analog used as a therapeutic agent in treating these conditions. The interaction between GLP-1 (7-36) and DPP-4 forms a basis for developing DPP-4 inhibitors as a treatment strategy for managing diabetes.